![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg−1) caused a large (45%) reduction in mean arterial blood pressure (MABP) and a 40–60% reduction in TBF. Low-dose hydralazine (0.1 mg kg−1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg−1) and calcitonin-gene related peptide (CGRP, 1 nmol kg−1) which caused a 20% reduction in MABP led to a 50–60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.